First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age
| العنوان: | First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age |
|---|---|
| المؤلفون: | Filomena Calabrese, Carlo Molino, Vincenzo Sforza, Giovanni Conzo, Annalisa Pappalardo, Angelica Petrillo, Luca Pompella, Maria Maddalena Laterza, M. Biglietto, Michele Orditura, Marianna Caterino, Ferdinando De Vita, Vega Iranzo, Jole Ventriglia, Giuseppe Tirino, Fortunato Ciardiello |
| المساهمون: | Petrillo, A., Pappalardo, A., Calabrese, F., Tirino, G., Pompella, L., Ventriglia, J., Laterza, M. M., Caterino, M., Sforza, V., Iranzo, V., Biglietto, M., Orditura, M., Ciardiello, F., Conzo, G., Molino, C., De Vita, F. |
| المصدر: | Journal of Gastrointestinal Oncology r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia instname |
| بيانات النشر: | AME Publishing Company, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, medicine.medical_specialty, Nab-paclitaxel plus gemcitabine, Pancreatic cancer (PC), Anemia, Metastatic pancreatic adenocarcinoma, ECOG Performance Status, Neutropenia, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Elderly, Internal medicine, medicine, Progression-free survival, Adverse effect, Univariate analysis, business.industry, First-line chemotherapy, Incidence (epidemiology), medicine.disease, Gemcitabine, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Original Article, business, medicine.drug |
| الوصف: | Background: Nab-paclitaxel plus gemcitabine represents one of the standard regimens for first line treatment of metastatic pancreatic cancer (mPC). Few data are available on nab-paclitaxel plus gemcitabine in geriatric population. Our study aims to show whether this schedule can be feasible in the elderly as first-line treatment for mPC. Methods: We retrospectively analyzed the data of 64 mPC patients (>= 65 years old) treated according to the MPACT schedule. Results: Median age was 69.5 years (range, 65-80 years); after a median of 5 cycles administered (range, 1-12), the most common adverse events (AEs) were grade 2 alopecia (46.9%), anemia (17.2%) and hypertransaminasemia (10.9%); all grades neutropenia occurred in 20.3% of pts. Global incidence of grade 3 and 4 toxicities were 26.5% and 0%, respectively, and no patients stopped treatment due to unacceptable toxicity. Stable disease (SI)) was observed in 31.2% of patients, with a disease control rate (DCR) and overall response rate of 57.8% and 26.6%, respectively. After a median follow-up of 18 months, median progression free survival (PFS) was 8 months (95% CI: 6.3-9.6) and median OS was 12.0 months (95% CI: 8.4-15.6). The univariate analysis for overall survival (OS) showed that only ECOG performance status was an independent prognostic factor for survival. Conclusions: Nab-paclitaxel plus gemcitabine schedule is feasible and effective in the "daily clinical practice" geriatric population. |
| اللغة: | English |
| تدمد: | 2078-6891 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e78aab724c76f1c740ab984c50752597Test https://europepmc.org/articles/PMC6776800Test/ |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e78aab724c76f1c740ab984c50752597 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20786891 |
|---|